(Q73123089)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10537964%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

title

Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10537964%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference

1 reference

S H Hamilton

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10537964%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

D A Revicki

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10537964%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

E T Edgell

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10537964%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

L A Genduso

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10537964%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

G Tollefson

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10537964%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

publication date

1 May 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10537964%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10537964%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10537964%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

page(s)

469-480

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10537964%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10537964%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/00019053-199915050-00005

1 November 2019

exact match

0 references

cites work

Pharmacoeconomics of antipsychotic drug therapy

1 reference

12 December 2020

The costs of schizophrenia. Assessing the burden.

1 reference

12 December 2020

Savings in hospital bed-days related to treatment with clozapine.

1 reference

12 December 2020

Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia.

1 reference

12 December 2020

Conventional antipsychotic medications for schizophrenia

1 reference

12 December 2020

Motor and mental aspects of extrapyramidal syndromes

1 reference

12 December 2020

Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients.

1 reference

12 December 2020

Clozapine's cost-benefits

1 reference

12 December 2020

Treatment of schizophrenia

1 reference

12 December 2020

Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia

1 reference

12 December 2020

The pharmacoeconomics of clozapine: a review.

1 reference

12 December 2020

Suicide in schizophrenics, manics, depressives, and surgical controls. A comparison with general population suicide mortality

1 reference

12 December 2020

The distinction between cost and charges

1 reference

12 December 2020

Economic analysis and clinical trials

1 reference

12 December 2020

Expenditures on services for persons with acquired immunodeficiency syndrome under a Medicaid home and community-based waiver program. Are selection effects important?

1 reference

12 December 2020

Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial

1 reference

12 December 2020

Recent advances in the pharmacotherapy of schizophrenia

1 reference

12 December 2020

A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

1 reference

12 December 2020

Psychopharmacologic treatment of schizophrenia

1 reference

12 December 2020

Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study

1 reference

12 December 2020

One hundred years of schizophrenia: a meta-analysis of the outcome literature.

1 reference

12 December 2020

Pharmacoeconomic evaluation of treatments for refractory schizophrenia: clozapine-related studies

1 reference

12 December 2020

Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia.

1 reference

12 December 2020

Pharmacologic advances in the treatment of schizophrenia

1 reference

12 December 2020

Clozapine's effectiveness for patients in state hospitals: results from a randomized trial.

1 reference

12 December 2020

Statistical analysis of cost outcomes in a randomized controlled clinical trial

1 reference

12 December 2020

A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients

1 reference

12 December 2020

Health insurance and the demand for medical care: evidence from a randomized experiment

1 reference

12 December 2020

1 reference

12 December 2020

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1 reference

12 December 2020

Evaluating outcomes of treatments for persons with psychotic disorders.

1 reference

12 December 2020

Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.

1 reference

12 December 2020

Estimating costs in the economic evaluation of medical technologies

1 reference

12 December 2020

The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome

1 reference

12 December 2020

Excess mortality in schizophrenia and affective disorders. Do suicides and accidental deaths solely account for this excess?

1 reference

12 December 2020

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

12 December 2020

A selective review of recent North American long-term followup studies of schizophrenia

1 reference

12 December 2020

Cost of relapse in schizophrenia

1 reference

12 December 2020

A mental health capitation program: II. Cost-benefit analysis.

1 reference

12 December 2020

Anchoring the BPRS: an aid to improved reliability

1 reference

12 December 2020

Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia

1 reference

12 December 2020

Prognosis in schizophrenia. A ten-year follow-up of first admissions

1 reference

12 December 2020